Worth reading
42Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
25.4
% (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter1 June 2025–28 February 2026ConsolidatedJapanese GAAPNet Sales18,168¥ millionYear on year +2.3%Progress 73.1%
Operating profit1,703¥ millionYear on year +25.4%Progress 85.2%
Ordinary income1,785¥ millionYear on year +29.4%Progress 85.8%
Net income attributable to owners of the parent1,299¥ millionYear on year -13.2%Progress 86.6%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥219.61
Financial position at period-end
Total assets23,436¥ million
of which net assets 15,926 ¥ millionEquity ratio 68.0%vs. prior year-end +2.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueChemicals Business ¥17,150 million (YoY +3.0%), Healthcare Business ¥1,017 million (YoY -7.2%)
Segment profitChemicals Business ¥1,465 million (YoY +28.5%), Healthcare Business ¥237 million (YoY +9.2%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥24,850 million (YoY +4.8%)
Operating profit¥2,000 million (YoY +3.9%)
Ordinary income¥2,080 million (YoY +6.5%)
Net income¥1,500 million (YoY -16.9%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast¥92 → ¥76
Factors Behind Changes in Business Performance
Sales of detergents and other products remained firm. Profit increased in the Chemicals segment due to expanded product sales and measures to contain raw material costs. Profit also increased in the Healthcare segment due to cost reductions in freight, advertising and other expenses.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Impairment lossNo material impairment losses (no material matters to disclose)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥1,000 thousand, Gain on sale of shares in a subsidiary ¥92,069 thousand / Extraordinary loss Loss on disposal and sale of non-current assets ¥4,644 thousand
Depreciation and amortization¥394,660 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo
Issued Shares at Period-End5,943,052 shares
Treasury Shares at Period-End14,502 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 June 2025–28 February 2026 |
| Net Sales | ¥18,168 million (YoY +2.3%) |
| Operating profit | ¥1,703 million (YoY +25.4%) |
| Ordinary income | ¥1,785 million (YoY +29.4%) |
| Profit attributable to owners of the parent | ¥1,299 million (YoY -13.2%) |
| Net income per share | ¥219.61 |
| Equity ratio | End of the current fiscal period 68.0% / End of previous period 65.3% |
| Total assets | ¥23,436 million |
| Net assets | ¥15,926 million |
| Full-year earnings forecast | Net Sales ¥24,850 million (YoY +4.8%) / Operating profit ¥2,000 million (YoY +3.9%) / Ordinary income ¥2,080 million (YoY +6.5%) / Net income ¥1,500 million (YoY -16.9%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥92 → ¥76 |
| Segment revenue | Chemicals Business ¥17,150 million (YoY +3.0%), Healthcare Business ¥1,017 million (YoY -7.2%) |
| Segment profit | Chemicals Business ¥1,465 million (YoY +28.5%), Healthcare Business ¥237 million (YoY +9.2%) |
| Depreciation and amortization | ¥394,660 thousand |
| Impairment loss | No material impairment losses (no material matters to disclose) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥1,000 thousand, Gain on sale of shares in a subsidiary ¥92,069 thousand / Extraordinary loss Loss on disposal and sale of non-current assets ¥4,644 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 5,943,052 shares |
| Treasury Shares at Period-End | 14,502 shares |
| Factors Behind Changes in Business Performance | Sales of detergents and other products remained firm. Profit increased in the Chemicals segment due to expanded product sales and measures to contain raw material costs. Profit also increased in the Healthcare segment due to cost reductions in freight, advertising and other expenses. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as sales of detergents and other products remained firm. Operating profit and ordinary profit rose due to expanded product sales in the Chemicals segment and measures to contain raw material costs. No reason was given for the decline in quarterly net income attributable to owners of the parent.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.